Takeda Picks Next Big Thing In Immunotherapy: Gamma Delta T Cells

Takeda is aiming to get ahead in what it believes is an emerging area with big potential in immunotherapy: gamma delta T-cells. It has signed a deal with GammaDelta Therapeutics that gives it a purchase option on the UK-based, Abingworth-backed start-up. GammaDelta's CEO, former GSK executive Paolo Paoletti, and the head of Takeda's external innovation center, Dan Curran, spoke to Scrip.